40,062 Shares in CG Oncology, Inc. $CGON Acquired by Legal & General Group Plc

Legal & General Group Plc purchased a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) in the second quarter, Holdings Channel reports. The fund purchased 40,062 shares of the company’s stock, valued at approximately $2,846,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Fiduciary Financial Advisors acquired a new position in shares of CG Oncology during the second quarter valued at $28,000. NFSG Corp acquired a new stake in CG Oncology in the first quarter worth about $34,000. Comerica Bank grew its position in CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after buying an additional 515 shares in the last quarter. LPL Financial LLC grew its position in CG Oncology by 9.8% in the 4th quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock valued at $257,000 after buying an additional 551 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in CG Oncology during the 1st quarter valued at about $74,000. Institutional investors own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on CGON. Wedbush boosted their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of CG Oncology in a research note on Wednesday, July 29th. Wolfe Research started coverage on CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Royal Bank Of Canada decreased their price target on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. lifted their price target on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CG Oncology has an average rating of “Moderate Buy” and a consensus target price of $83.18.

CG Oncology Trading Up 0.5%

Shares of NASDAQ CGON opened at $74.67 on Friday. CG Oncology, Inc. has a twelve month low of $29.85 and a twelve month high of $80.97. The firm has a 50-day moving average of $73.63 and a two-hundred day moving average of $67.25. The company has a market capitalization of $6.62 billion, a price-to-earnings ratio of -27.76 and a beta of 0.24.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%.The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. As a group, research analysts predict that CG Oncology, Inc. will post -3.27 earnings per share for the current year.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 24,165 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total value of $1,816,241.40. Following the transaction, the director owned 24,165 shares of the company’s stock, valued at approximately $1,816,241.40. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard Post sold 1,000 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $74.54, for a total value of $74,540.00. Following the sale, the director owned 1,000 shares of the company’s stock, valued at $74,540. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 37,129 shares of company stock worth $2,683,857. Corporate insiders own 4.80% of the company’s stock.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.